Plain-English fact sheet
Semax
Also known as Semax heptapeptide, ACTH(4-7)-Pro-Gly-Pro
Semax is promoted for cognition and neuroprotection, but it is not FDA approved and reliable human evidence is sparse, geographically narrow, and difficult to generalize.
Quick answer
Semax is a synthetic seven-amino-acid peptide studied mainly in Russian stroke and neuroscience research. It is not FDA approved for stroke, cognition, focus, memory, mood, or any other use.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Semax?
Semax combines a fragment related to adrenocorticotropic hormone with a Pro-Gly-Pro sequence and is designed to have neuroactive effects without the full hormone's endocrine activity.
Most modern mechanistic claims come from animal, cell, or gene-expression studies rather than confirmatory human outcome trials.
Why are people interested in it?
It is marketed online as a nootropic or neuroprotective peptide for memory, attention, stress, and recovery after neurologic injury.
The human literature is dominated by older, small studies with limited reporting, while FDA identifies route-specific safety and peptide-quality uncertainties.
Current regulatory status
Semax has no FDA-approved drug product or use. FDA's current compounding safety page identifies potential immune and impurity risks and limited safety information for proposed routes.
What is it approved for?
No FDA-approved use. This matters because clinical-trial participation and products marketed online are not the same as an approved medicine.
What is it being studied for?
Investigational areas
- Neurologic recovery and neuroprotection
- Cognitive and stress-related outcomes
Evidence snapshot
Small older human stroke studies exist, but they do not establish a reliable modern evidence base for cognitive enhancement or routine neurologic treatment. Much of the supporting literature is preclinical.
Potential benefits being researched
- A small 1997 controlled study in acute ischemic stroke reported signals in neurologic recovery, but its design and reporting do not support broad clinical conclusions.
- Preclinical studies suggest effects on neurotrophic, inflammatory, and gene-expression pathways; those are hypotheses, not proof of better cognition in people.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- FDA identifies possible immune reactions, aggregation, peptide impurities, and limited route-specific human safety information.
- There is no mature adverse-event database for repeated use in healthy people or people with neurologic disease.
- Unapproved products add uncertainty about identity, purity, strength, sterility, and labeling.
What we still do not know
- Whether Semax improves cognition, memory, attention, or function in well-controlled modern trials
- Short- and long-term safety across populations
- Whether older stroke findings can be replicated with current trial methods and standard care
- The identity and quality of products marketed under the name
Plain-English takeaway
Semax is biologically interesting but clinically underproved. Its reputation as a cognitive enhancer is much larger than its reliable human evidence base.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1FDA: safety risks for selected compounded bulk substances
FDA's current substance-specific summary of evidence gaps and potential safety risks.
- 2Controlled clinical study of Semax in ischemic stroke
Small older human study with important design, reporting, and generalizability limits.
- 3Preclinical Semax gene-expression study
Rat ischemia study supporting mechanistic hypotheses, not human cognitive benefit.
- 4FDA: understanding the risks of compounded drugs
FDA overview explaining that compounded drugs are not reviewed before marketing for safety, effectiveness, or quality.